We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-17.58%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$221M
AUM Growth
-$96.8M
Cap. Flow
-$24.3M
Cap. Flow %
-11.03%
Top 10 Hldgs %
60.19%
Holding
74
New
20
Increased
14
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
HOLX
Hologic
HOLX
+$22.6M
2
SNY icon
Sanofi
SNY
+$19.6M
3
PFE icon
Pfizer
PFE
+$18.3M
4
SIBN icon
SI-BONE Inc
SIBN
+$15.6M
5
JNJ icon
Johnson & Johnson
JNJ
+$6.88M

Top Sells

Rank Stock Value
1
COR icon
Cencora
COR
+$18.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$16.2M
3
LH icon
Labcorp
LH
+$13.7M
4
ELV icon
Elevance Health
ELV
+$10.5M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.6%
2 Industrials 2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNC icon
26
Centene
CNC
$32.5B
$2.27M 1.03%
+38,196
New +$2.32M
DVA icon
27
DaVita
DVA
$11.7B
$2.07M 0.94%
27,164
+15,162
+126% +$1.19M
XRAY icon
28
Dentsply Sirona
XRAY
$2.43B
$2.04M 0.93%
52,645
-4,080
-7% -$208K
TRIL
29
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.93M 0.87%
+477,704
New +$1.81M
CRL icon
30
Charles River Laboratories
CRL
$12.8B
$1.66M 0.75%
+13,147
New +$1.97M
GWPH
31
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.48M 0.67%
16,890
-12,820
-43% -$1.36M
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
$1.45M 0.66%
+58,787
New +$2.14M
INSM icon
33
Insmed
INSM
$28.6B
$1.19M 0.54%
+74,365
New +$1.76M
ATRC icon
34
AtriCure
ATRC
$2.11B
$1.12M 0.51%
+33,453
New +$1.2M
FATE icon
35
Fate Therapeutics
FATE
$326M
$905K 0.41%
40,732
-94,290
-70% -$2.38M
IQV icon
36
IQVIA
IQV
$39.3B
$899K 0.41%
8,332
-41,449
-83% -$5.92M
AXSM icon
37
Axsome Therapeutics
AXSM
$10.9B
$728K 0.33%
12,367
+1,216
+11% +$99.1K
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$696K 0.32%
+87,676
New +$673K
RNAC icon
39
Cartesian Therapeutics
RNAC
$268M
$615K 0.28%
8,510
+7,650
+890% +$739K
IOVA icon
40
Iovance Biotherapeutics
IOVA
$2.83B
$605K 0.27%
20,207
-148,339
-88% -$3.93M
LAB icon
41
Standard BioTools
LAB
$314M
$590K 0.27%
232,291
-802,342
-78% -$2.64M
PRNB
42
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$530K 0.24%
8,927
-57,230
-87% -$3.34M
MGNX icon
43
MacroGenics
MGNX
$257M
$510K 0.23%
87,703
-35,197
-29% -$320K
HCA icon
44
HCA Healthcare
HCA
$89.5B
$509K 0.23%
+5,666
New +$734K
GNCA
45
DELISTED
Genocea Biosciences, Inc.
GNCA
$455K 0.21%
264,307
+26,100
+11% +$52.7K
ADAP
46
DELISTED
Adaptimmune Therapeutics
ADAP
$435K 0.2%
+159,826
New +$530K
OVID icon
47
Ovid Therapeutics
OVID
$491M
$347K 0.16%
+116,297
New +$392K
PETS icon
48
PetMed Express
PETS
$42.3M
$287K 0.13%
+9,964
New +$261K
KDMN
49
DELISTED
Kadmon Holdings, Inc.
KDMN
$256K 0.12%
+61,188
New +$263K
ABBV icon
50
AbbVie
ABBV
$435B
– –
-98,596
Closed -$8.73M
1
2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Endurant Capital Management held 74 positions worth $221M, down 30% from $317M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Endurant Capital Management withdrew a net $24.3M in Q1 2020, closing 23 positions and reducing 17 holdings. Its most notable exit was Cencora, an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Industrials.

Against the trend, Endurant Capital Management opened a new position in Hologic worth $16.6M.

  • Endurant Capital Management's largest Q1 2020 buy was Hologic: 473,667 shares worth $16.6M.
  • Endurant Capital Management added most to SI-BONE Inc in Q1 2020, an estimated $15.6M increase.
  • Endurant Capital Management's biggest Q1 2020 reduction was Bristol-Myers Squibb, cutting an estimated $16.2M.
  • Endurant Capital Management fully exited Cencora in Q1 2020, selling an estimated $18.6M.
  • Endurant Capital Management's ten largest holdings make up 60% of its $221M portfolio in Q1 2020.
  • Endurant Capital Management opened 20 new positions and closed 23 in Q1 2020.
  • Endurant Capital Management's portfolio value fell 30% quarter-over-quarter to $221M.

Based on Endurant Capital Management's 13F filing for Q1 2020, filed 15 May 2020.